Saxenda: latest news - GoINPHARMA
Sunday, 18 November 2018 - 11:17

Saxenda

Novo focuses on new obesity therapy Semaglutide

Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…